Latest International and Indian Pharma Company Announcements
Curated latest announcements on partnerships, product launches, regulatory approvals, M&A deals, and corporate developments from global and Indian pharmaceutical companies.
Major Indian Pharmaceutical Company Announcements
1. Piramal Pharma Limited Announces Q1 FY27 Financial Results
- Announcement Date: July 29, 2026
- Company: Piramal Pharma Limited
- Details: Reported a 17% YoY revenue growth to ₹2,270 Crore driven by its CDMO and hospital generics businesses, alongside a 72% jump in EBITDA.
2. Torrent Pharmaceuticals Completes Amalgamation with JB Chemicals
- Announcement Date: July 28, 2026
- Company: Torrent Pharmaceuticals Ltd.
- Details: Formally finalized the merger of JB Chemicals into Torrent Pharma to consolidate its dominant market share in India’s chronic cardiac and gastrointestinal therapy segments.
3. Sun Pharma Receives ANVISA Approval for Semaglutide in Brazil
- Announcement Date: July 29, 2026
- Company: Sun Pharmaceutical Industries Ltd.
- Details: Secured regulatory clearance from Brazil’s health authority to launch once-weekly Semaglutide formulations in Latin America’s largest diabetes market.
4. Sun Pharma Finalizes $11.8 Billion Acquisition of Organon
- Announcement Date: July 24, 2026
- Company: Sun Pharmaceutical Industries Ltd.
- Details: Completed the largest cross-border transaction in Indian pharma history, absorbing Organon’s global women’s health and biosimilar commercial networks.
5. Wockhardt Advances Global Commercialization of Anesthetic Cypsedo
- Announcement Date: July 2026
- Company: Wockhardt Limited
- Details: Received regulatory green light for Cypsedo (cipepofol) in major export markets as a safer, short-acting intravenous general anesthetic alternative to propofol.
6. Biocon Biologics Expands Biosimilars Agreements across Europe & LATAM
- Announcement Date: July 2026
- Company: Biocon Biologics
- Details: Signed multi-country commercial licensing deals for its rh-Insulin and monoclonal antibody biosimilar formulations following successful regulatory site inspections.
7. Zydus Lifesciences Out-Licenses Oral MASH Candidate
- Announcement Date: July 15, 2026
- Company: Zydus Lifesciences Ltd.
- Details: Announced an international co-development partnership for its small-molecule drug candidate targeting non-alcoholic steatohepatitis (MASH) after positive Phase II clinical readouts.
8. Lupin Receives US FDA Approval for Generic Respiratory Aerosol Inhalers
- Announcement Date: July 2026
- Company: Lupin Limited
- Details: Secured Abbreviated New Drug Application (ANDA) clearance for a generic inhalation aerosol targeting chronic obstructive pulmonary disease (COPD) and asthma in the US market.
9. Cipla Expands Global Health Supply Partnership for HIV & TB Therapies
- Announcement Date: July 2026
- Company: Cipla Ltd.
- Details: Partnered with global health organizations to expand high-volume, low-cost access to fixed-dose combination anti-retroviral and pediatric tuberculosis medications in lower-income countries.
10. Dr. Reddy’s Laboratories Launches First-to-Market Monoclonal Biosimilar
- Announcement Date: July 2026
- Company: Dr. Reddy’s Laboratories Ltd.
- Details: Rollout of a biosimilar monoclonal antibody in oncology across emerging markets following local phase III equivalency validation.
Major International Pharmaceutical Company Announcements
1. Sanofi Posts Q2 2026 Financials & Upgrades Full-Year Guidance
- Announcement Date: July 30, 2026
- Company: Sanofi S.A.
- Details: Upgraded full-year EPS projections as blockbuster immunology drug Dupixent surpassed €5.2 billion in quarterly revenue alone.
2. GSK Secures First Lung Cancer Approval with Zidesamtinib (Jideytro)
- Announcement Date: July 22, 2026
- Company: GSK plc
- Details: Won US FDA clearance for Jideytro (zidesamtinib) in ROS1-positive non-small cell lung cancer, marking GSK’s entry into targeted lung oncology.
3. Eli Lilly Acquires AtaiBeckley for $2.8 Billion
- Announcement Date: July 16, 2026
- Company: Eli Lilly and Company
- Details: Executed the largest mental-health acquisition in recent pharma history to acquire clinical-stage nasal spray candidate BPL-003 for treatment-resistant depression.
4. Eli Lilly Unveils Phase 3 Retatrutide Results Showing 22.6% Weight Loss
- Announcement Date: July 23, 2026
- Company: Eli Lilly and Company
- Details: Announced landmark trial results for its GIP/GLP-1/glucagon triple agonist, setting a new benchmark for therapeutic weight reduction in clinical trials.
5. Merck Wins Landmark Approval for First Oral PCSK9 Inhibitor Lipfendra
- Announcement Date: July 16, 2026
- Company: Merck & Co., Inc.
- Details: Received US FDA approval for Lipfendra (enlicitide), the world’s first once-daily oral pill designed to replace injectable cholesterol therapies.
6. Roche Reports H1 2026 Revenue of CHF 30.4 Billion
- Announcement Date: July 23, 2026
- Company: Roche Group
- Details: Posted a 6% sales gain driven by rapid market adoption of Vabysmo (eye disease) and Phesgo (breast cancer).
7. Celcuity Receives Approval for Revtorpyk (Gedatolisib) in Advanced Breast Cancer
- Announcement Date: July 14, 2026
- Company: Celcuity Inc. / Pfizer Partnership
- Details: FDA approved Revtorpyk in combination with endocrine therapy after Phase 3 trial data showed a 76% reduction in disease progression risk.
8. Novartis Granted Traditional FDA Approval for Fabhalta in IgA Nephropathy
- Announcement Date: July 17, 2026
- Company: Novartis AG
- Details: Converted accelerated approval to full traditional approval for Fabhalta (iptacopan), the first complement inhibitor proven to slow kidney function decline.
9. Johnson & Johnson Raises Revenue Guidance Past $100 Billion
- Announcement Date: July 20, 2026
- Company: Johnson & Johnson
- Details: Elevated full-year 2026 revenue guidance to over $101 billion following strong global adoption of its oncology and medtech portfolios.
10. Vera Therapeutics Wins Accelerated FDA Approval for Atacicept
Details: FDA granted accelerated approval to Atacicept for primary IgA nephropathy based on a 42% reduction in proteinuria at 9 months.
Announcement Date: July 7, 2026
Company: Vera Therapeutics